Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Harper Sean E
Relationship:   10% Owner
City:   Thousand Oaks
State:   CA
   
Insider Summary:
  
   
Companies Owned :   3    
Direct Shares   9,846,811    

Indirect Shares

   735,984      
Direct Value   $64,300,457    

Indirect Value

   $11,680,066      
Total Shares   10,582,795      
Total Value   $75,980,523      


Amgen Inc $17,892,401 Acelyrin, Inc. $46,408,055 Amgen Inc $17,892,401 Acelyrin, Inc. $46,408,055
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    1   
    0    

     Stock price went up :
    0   
    0    
     Stock price went down :
    1   
    0    
   
     Gain/Loss Ratio :
   -1.0   
   0.0   
     Percentage Gain/Loss :
   -71.0%
   0.0%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Amgen Inc AMGN EVP, Research & Develo... 2018-07-16 56,082 0    Premium*  
            Acelyrin, Inc. SLRN 10% Owner 2023-05-09 9,790,729 2023-05-09 0    Premium*  
            Kyverna Therapeutics KYTX 10% Owner 2024-02-12 0 2024-02-12 735,984    Premium*  
* Premium Members only  

Records found :    64         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 1 of 3
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
AMGN Amgen Inc EVP, Research & Development   •       –      –    2012-03-14 4 A $0.00 $0 D/D 4,140 46,290 0 -
AMGN Amgen Inc EVP, Research & Development   •       –      –    2012-04-27 4 A $0.00 $0 D/D 8,654 52,911 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2013-01-28 4 A $0.00 $0 D/D 7,477 59,981 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2013-03-06 4 A $0.00 $0 D/D 13,257 73,238 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2014-01-31 4 A $0.00 $0 D/D 5,044 69,439 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2014-03-05 4 A $0.00 $0 D/D 14,724 84,163 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2015-01-30 4 A $0.00 $0 D/D 3,940 49,585 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2015-03-04 4 A $0.00 $0 D/D 54,577 104,162 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2016-03-02 4 A $0.00 $0 D/D 45,268 89,162 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2016-05-03 4 A $0.00 $0 D/D 4,477 46,725 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2017-05-01 4 A $0.00 $0 D/D 4,551 60,496 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-03-07 4 A $0.00 $0 D/D 15,118 67,207 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-04-27 4 A $0.00 $0 D/D 4,508 61,296 0 -
SLRN Acelyrin, Inc. 10% Owner   –       –       •   2023-05-09 4 A $0.00 $0 D/D 8,540,729 8,540,729 0 -
KYTX Kyverna Therapeutics 10% Owner   –       –       •   2024-02-12 4 A $0.00 $0 I/I 4,523,924 735,984 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2017-10-09 4 AS $185.95 $283,574 D/D (1,525) 59,156 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2017-11-13 4 AS $171.58 $261,660 D/D (1,525) 57,631 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2017-12-12 4 AS $176.83 $269,666 D/D (1,525) 56,106 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-01-16 4 AS $185.62 $283,071 D/D (1,525) 54,673 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-02-14 4 AS $174.18 $265,625 D/D (1,525) 52,089 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-03-16 4 AS $189.75 $289,369 D/D (1,525) 65,682 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-04-12 4 AS $172.68 $263,337 D/D (1,525) 56,788 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-05-14 4 AS $174.10 $265,503 D/D (1,525) 59,035 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-06-12 4 AS $184.27 $281,012 D/D (1,525) 57,510 0 -
AMGN Amgen Inc EVP, Research & Development   •       •      –    2018-07-16 4 AS $195.71 $298,458 D/D (1,525) 56,082 0 -
  64  Records found
  1  2   3      
  Page 1 of 3  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us